Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Protagonist Therapeutics
Biotech
Zealand sells rights to Takeda’s blood cancer drug for $100M
As the FDA mulls whether to approve Takeda and Protagonist’s rusfertide, Zealand sold its rights to the blood cancer drug in return for $100 million.
James Waldron
Aug 13, 2026 5:05am
Silence brings the noise to Takeda with phase 2 blood cancer win
Aug 10, 2026 7:31am
Protagonist hands rusfertide rights to Takeda for $475M payday
Apr 28, 2026 11:05am
Protagonist prefers $400M from Takeda over rusfertide US profits
Feb 26, 2026 10:00am
Merck mulls PV program’s future while Takeda takes victory lap
Dec 8, 2025 4:30pm
J&J eyes takeover of immunology partner Protagonist: WSJ
Oct 10, 2025 2:30pm
